Molecular markers are essential for personalized medicine, where treatments are tailored to the individual characteristics of each patient's cancer. For example, the presence of EGFR mutations in non-small cell lung cancer can make patients eligible for targeted therapies like tyrosine kinase inhibitors. Similarly, the overexpression of the HER2 protein in breast cancer patients can make them suitable candidates for drugs like trastuzumab.
